Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones
January 09, 2023 07:00 ET | Tenaya Therapeutics, Inc.
Phase 1b Clinical Trial for TN-201 in MYBPC3-associated HCM Patients Expected to Begin Dosing in Third Quarter 2023; Data Anticipated in 2024 Data from First-in-Human Clinical Trial of TN-301...
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors
December 07, 2022 16:30 ET | Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference
November 23, 2022 09:00 ET | Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022 16:05 ET | Tenaya Therapeutics, Inc.
Extends Cash Runway to Mid-2024 Commenced Dosing in Phase 1 Clinical Trial of TN-301; Data Expected in 2023 Plans to Submit TN-201 IND by Year End SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 ...
Imara-Logo-Color-RGB.jpg
Enliven Therapeutics and Imara Announce Merger Agreement
October 13, 2022 16:35 ET | Imara, Inc.
Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven’s portfolio of precision oncology programsCombined company is expected to have a cash balance of...
Sensei_Logo_RGB_Logo_Full-Color.png
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
September 30, 2022 16:05 ET | Sensei Biotherapeutics
- SNS-101 demonstrated a favorable pharmacokinetic profile, enhanced anti-tumor effects in combination with anti-PD-1 antibodies and a significantly improved cytokine release profile as compared to a...
Sensei_Logo_RGB_Logo_Full-Color.png
Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
September 21, 2022 16:05 ET | Sensei Biotherapeutics
BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for...
Sensei_Logo_RGB_Logo_Full-Color.png
Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer
June 01, 2022 07:30 ET | Sensei Biotherapeutics
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next-generation therapeutics for cancer,...
sensei.jpg
Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference
May 25, 2022 07:30 ET | Sensei Biotherapeutics
BOSTON, May 25, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
sensei.jpg
Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
May 10, 2022 07:30 ET | Sensei Biotherapeutics
- SNS-101 preclinical data provide encouraging validation of pH-sensitive approach to inhibiting VISTA with high selectivity to treat solid tumors - - Cash runway extended into the first quarter of...